Artwork
iconShare
 
Manage episode 516061454 series 2409123
Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Deputy Editor Ali Landman speaks with Matthias Preusser about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.

  continue reading

216 episodes